Free Trial
NASDAQ:KALA

KALA BIO (KALA) Stock Price, News & Analysis

KALA BIO logo
$7.50 +0.73 (+10.78%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.60 +0.09 (+1.27%)
As of 08/1/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About KALA BIO Stock (NASDAQ:KALA)

Key Stats

Today's Range
$6.50
$7.63
50-Day Range
$3.52
$8.40
52-Week Range
$2.92
$11.20
Volume
138,258 shs
Average Volume
216,393 shs
Market Capitalization
$48.38 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$13.00
Consensus Rating
Buy

Company Overview

KALA BIO Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
74th Percentile Overall Score

KALA MarketRank™: 

KALA BIO scored higher than 74% of companies evaluated by MarketBeat, and ranked 237th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    KALA BIO has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    KALA BIO has only been the subject of 3 research reports in the past 90 days.

  • Read more about KALA BIO's stock forecast and price target.
  • Earnings Growth

    Earnings for KALA BIO are expected to grow in the coming year, from ($10.84) to ($6.22) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of KALA BIO is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of KALA BIO is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    KALA BIO has a P/B Ratio of 3.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about KALA BIO's valuation and earnings.
  • Percentage of Shares Shorted

    6.11% of the float of KALA BIO has been sold short.
  • Short Interest Ratio / Days to Cover

    KALA BIO has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in KALA BIO has recently increased by 3.29%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    KALA BIO does not currently pay a dividend.

  • Dividend Growth

    KALA BIO does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.11% of the float of KALA BIO has been sold short.
  • Short Interest Ratio / Days to Cover

    KALA BIO has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in KALA BIO has recently increased by 3.29%, indicating that investor sentiment is decreasing.
  • News Sentiment

    KALA BIO has a news sentiment score of -0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for KALA BIO this week, compared to 1 article on an average week.
  • Search Interest

    2 people have searched for KALA on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, KALA BIO insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $162,876.00 in company stock.

  • Percentage Held by Insiders

    Only 8.32% of the stock of KALA BIO is held by insiders.

  • Percentage Held by Institutions

    Only 24.61% of the stock of KALA BIO is held by institutions.

  • Read more about KALA BIO's insider trading history.
Receive KALA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for KALA BIO and its competitors with MarketBeat's FREE daily newsletter.

KALA Stock News Headlines

KALA BIO (NASDAQ:KALA) Upgraded to "Hold" at Wall Street Zen
REVEALED FREE: Our top 3 stocks to own in 2025 and beyond
Every time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (including the losers!).
See More Headlines

KALA Stock Analysis - Frequently Asked Questions

KALA BIO's stock was trading at $6.94 at the start of the year. Since then, KALA stock has increased by 8.1% and is now trading at $7.50.

KALA BIO, Inc. (NASDAQ:KALA) released its quarterly earnings results on Friday, March, 28th. The company reported ($1.74) earnings per share for the quarter, beating the consensus estimate of ($2.28) by $0.54.

KALA BIO's stock reverse split on the morning of Friday, October 21st 2022.The 1-50 reverse split was announced on Friday, October 21st 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, October 21st 2022. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split.

KALA BIO (KALA) raised $90 million in an initial public offering on Thursday, July 20th 2017. The company issued 6,000,000 shares at a price of $14.00-$16.00 per share. J.P. Morgan and BofA Merrill Lynch served as the underwriters for the IPO and Wells Fargo Securities and Wedbush PacGrow were co-managers.

KALA BIO's top institutional shareholders include AIGH Capital Management LLC (4.65%). Insiders that own company stock include Bros Advisors Lp Baker, Mark T Iwicki, Todd Bazemore, Romulus K Brazzell, Eric Trachtenberg, Darius Kharabi and Mary Reumuth.
View institutional ownership trends
.

Shares of KALA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that KALA BIO investors own include Plug Power (PLUG), Ovid Therapeutics (OVID), Fortress Biotech (FBIO), FuelCell Energy (FCEL), Workhorse Group (WKHS), Lipocine (LPCN) and Comtech Telecommunications (CMTL).

Company Calendar

Last Earnings
3/28/2025
Today
8/01/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KALA
CIK
1479419
Employees
30
Year Founded
N/A

Price Target and Rating

High Price Target
$15.00
Low Price Target
$12.00
Potential Upside/Downside
+73.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
3 Analysts

Profitability

EPS (Trailing Twelve Months)
($8.24)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$38.51 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-369.29%
Return on Assets
-64.99%

Debt

Debt-to-Equity Ratio
3.19
Current Ratio
1.99
Quick Ratio
1.99

Sales & Book Value

Annual Sales
$3.89 million
Price / Sales
12.44
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.02 per share
Price / Book
3.71

Miscellaneous

Outstanding Shares
6,450,000
Free Float
5,915,000
Market Cap
$48.38 million
Optionable
Not Optionable
Beta
-1.81

Social Links

(Almost)  Everything You Need To Know About The EV Market Cover

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

This page (NASDAQ:KALA) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners